Data on Biologics Reported by Laetitia Penso and Colleagues [Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS)]: Biotechnology – Biologics

2023 AUG 09 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Biotechnology - Biologics is the subject of a report. According to news originating from Creteil, France, by NewsRx correspondents, research stated, “Many biologics are available for psoriasis and have been compared in real-life studies based on their persistence (i.e., time between initiation and discontinuation). However, after first-line biologic failure, data are lacking on the choice of second-line biologic among the four available classes (TNF inhibitors [TNFi], interleukin 12/23 inhibitor [IL12/23i], IL17 inhibitors [IL17i] and IL23 inhibitors [IL23i]).”

Our news journalists obtained a quote from the research, “To compare the long-term persistence of available second-line biologics in psoriasis by prior exposure. This nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database. Participants were all adults with psoriasis, defined as having at least two prescriptions of a topical vitamin-D derivative within a 2-year period, with initiation of a second-line biologic between January 1, 2015 and December 31, 2021. We included patients who initiated a second-line biologic directly after first-line discontinuation (i.e., without a ‘wash-out’ period). End of follow-up was June 30, 2022. The discontinuation was defined by >90 days without filling a prescription for the same treatment after the period covered by the previous prescription. Comparison of persistence by biologic class involved using propensity score-weighted Cox models (inverse probability treatment weighting) and adjustment on specific systemic non-biologics (time-dependent variables). We included 8,693 patients (mean age 50 ? 14, 51% male); 2,824 (32%) started TNFi, 1,561 (18%) the IL12/23i, 2,707 (31%) IL17i and 1,601 (18%) IL23i. Overall, 1- and 3-year persistence rates were 60% and 30%. After weighting and adjustment, persistence was longer with the IL12/23i (weighted hazard ratio [HRw] 0.68 [95% CI 0.62-0.76]), IL17i (0.70 [0.64-0.78]) and IL23i (0.36 [0.31-0.42]) than TNFi, except after IL17i first-line treatment, with no difference between IL12/23i, IL17i and TNFi second-line persistence. Persistence was longer with IL23i as second-line treatment than the IL12/23i (HRw 0.53 [0.44-0.63]) and IL17i (0.51 [0.44-0.60]), regardless of first-line treatment, with no difference between IL12/23i and IL17i (HRw 0.97 [0.87-1.09]). This real-life study suggested longer persistence of IL23i than TNFi, IL17i and the IL12/23i in second-line treatment for psoriasis.”

According to the news editors, the research concluded: “Persistence rates for all biologics remained low at 3 years.”

This research has been peer-reviewed.

For more information on this research see: Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS). British Journal of Dermatology, 2023. British Journal of Dermatology can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - http://www.wiley.com/; British Journal of Dermatology - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2133)

The news correspondents report that additional information may be obtained from Laetitia Penso, EpiDermE, Paris Est Creteil University, 94010 Creteil, France. Additional authors for this research include Clarisse Marcombes, Alain Weill, Rosemary Dray-Spira, Mahmoud Zureik and Emilie Sbidian.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1093/bjd/ljad248. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher’s contact information for the British Journal of Dermatology is: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)